Latest news with #YiChen
Washington Post
30-05-2025
- Entertainment
- Washington Post
Xian Zhang and the BSO are a match made in heaven (or hell, as it were)
The last time conductor Xian Zhang came through town in 2024, she led the National Symphony Orchestra in — let me check my notes here — 'one of the more powerhouse showings from a guest conductor that I've witnessed since landing in D.C. four years ago.' So on Thursday evening it was an easy decision to head to Strathmore, where Zhang took up the first of three performances with the Baltimore Symphony Orchestra — a program of composers Yi Chen and Alexander Glazunov followed by a one-two punch of Tchaikovsky.
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating
On May 28, H.C. Wainwright analyst Yi Chen initiated coverage of NeuroPace, Inc. (NASDAQ:NPCE) with a Buy rating and a price target of $18. The rating comes after the company released preliminary results for one-year data in NAUTILUS study. On May 27, the company announced key results from its NAUTILUS study, the first clinical trial evaluating its RNS system for drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint at 12 weeks post-implant, demonstrating a low rate of serious adverse events and reinforcing the device's established safety profile. The analyst noted that the system demonstrated significant seizure reduction in the clinical stage. A close-up of a medical device being calibrated and tested in a clinical laboratory setting. Moreover, NeuroPace, Inc. (NASDAQ:NPCE) delivered robust results for the fiscal first quarter of 2025. The revenue grew more than 24% year-over-year to $22.52 million and surpassed expectations by $676,490, whereas the EPS of $-0.21 also exceeded consensus by $0.03. The analyst said that the stock has appreciated over 150% during the past year and the recent data from the study presents an attractive entry point for investors. NeuroPace Inc. (NASDAQ:NPCE) is a commercial-stage medical device company that develops the RNS system. RNS system is an implantable brain-responsive device designed to reduce or prevent seizures in people with drug-resistant epilepsy. While we acknowledge the potential of NPCE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NPCE and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50. This comes after the company released promising results from the Phase 2 TRANQUILITY trial of Pacibekitug. A scientist in a white lab coat working at a bench with biopharmaceutical equipment. Analyst Chen noted the results from the Phase 2 TRANQUILITY trial showed a significant reduction in high-sensitivity C-reactive protein (hs-CRP) levels in patients with kidney disease. The candidate also achieved a rapid and durable reduction in hs-CRP compared to the existing Ziltivekimab. Chen believes this can increase the potential market share of Tourmaline Bio, Inc.'s (NASDAQ:TRML) Pacibekitug. Tourmaline Bio, Inc. (NASDAQ:TRML) is a late-stage clinical biotechnology company developing treatments for life-altering immune and inflammatory diseases. Pacibekitug (TOUR006), is the company's lead product. It is a fully human monoclonal antibody designed to have a long half-life, high binding affinity to IL-6, and low immunogenicity. While we acknowledge the potential of TRML as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRML and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-04-2025
- Business
- Yahoo
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
ALAMEDA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced its participation in a virtual fireside chat hosted by Yi Chen, Ph.D., CFA, Managing Director of Equity Research at H.C. Wainwright & Company. As part of the presentation, Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D., will discuss Vivani's LIBERATE-1 clinical trial. LIBERATE-1 is a first-in-human study of NPM-115, the Company's miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management. Vivani anticipates topline data for LIBERATE-1 in mid-year 2025. Details for viewing the fireside chat are as follows: Date: Thursday, April 24, 2025 Time: 10 a.m. Eastern Time Weblink: About Vivani Medical, Inc. Leveraging its proprietary NanoPortal platform, Vivani develops therapeutic implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani's lead programs, NPM-139 (semaglutide implant) and NPM-115 (exenatide implant), are miniature, subdermal GLP-1 implants under development for chronic weight management in obese or overweight individuals designed for once or twice-yearly administration. Vivani's emerging pipeline also includes NPM-119, which refers to the Company's six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a semaglutide implant for the treatment of type 2 diabetes is also under consideration. These NanoPortal implants are designed to provide patients with the opportunity to experience the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of oral and injectable medications. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason why obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature, ultra long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers. For more information, please visit: Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 trial and reporting of trial results, Vivani's emerging development plans for NPM-115, NPM-139, NPM-119, and Vivani's technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-115, NPM-139, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities; risks related to the initiation, enrollment and conduct of Vivani's planned clinical trials and the results therefrom; Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business; market conditions and the ability of Cortigent to complete its intended spin-off from the Company. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact:Donald DwyerChief Business Officerinfo@ 506-8462 Investor Relations Contact:Jami TaylorInvestor Relations Advisorinvestors@ 506-8462 Media Contact:Sean LeousICR 866-4012Sign in to access your portfolio
